Literature DB >> 16887974

Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D.

Benjamin G Lilienfeld1, Carmen Garcia-Borges, Mark D Crew, Jörg D Seebach.   

Abstract

Cellular rejection mechanisms, including NK cells, remain a hurdle for successful pig-to-human xenotransplantation. Human anti-pig NK cytotoxicity depends on the activating receptor NKG2D. Porcine UL16-binding protein 1 (pULBP1) and porcine MHC class I chain-related protein 2 (pMIC2) are homologues of the human NKG2D ligands ULBP 1-4 and MICA and B, respectively. Although transcribed in porcine endothelial cells (pEC), it is not known whether pULBP1 and pMIC2 act as functional ligands for human NKG2D. In this study, surface protein expression of pULBP1 was demonstrated by flow cytometry using a novel pULBP1-specific polyclonal Ab and by cellular ELISA using NKG2D-Fc fusion protein. Reciprocally, pULBP1-Fc bound to primary human NK cells, whereas pMIC2-Fc did not. Transient and stable down-regulation of pULBP1 mRNA in pEC using short-interfering RNA oligonucleotide duplexes and short hairpin RNA, respectively, resulted in a partial inhibition of xenogeneic NK cytotoxicity through NKG2D in (51)Cr release assays. In contrast, down-regulation of pMIC2 mRNA did not inhibit NK cytotoxicity. Human NK cytotoxicity against pEC mediated by freshly isolated or IL-2-activated NK cells through NKG2D was completely blocked using anti-pULBP1 polyclonal Ab. In conclusion, this study suggests that pULBP1 is the predominant, if not only, functional porcine ligand for human NKG2D. Thus, the elimination of pULBP1 on porcine tissues represents an attractive target to protect porcine xenografts from human NK cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887974     DOI: 10.4049/jimmunol.177.4.2146

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse Model.

Authors:  H W Li; P Vishwasrao; M A Hölzl; S Chen; G Choi; G Zhao; M Sykes
Journal:  Am J Transplant       Date:  2016-08-10       Impact factor: 8.086

Review 2.  Innate cellular immunity and xenotransplantation.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Curr Opin Organ Transplant       Date:  2012-04       Impact factor: 2.640

Review 3.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 4.  Progress in xenotransplantation: overcoming immune barriers.

Authors:  Megan Sykes; David H Sachs
Journal:  Nat Rev Nephrol       Date:  2022-10-05       Impact factor: 42.439

Review 5.  Immunogenetics of the NKG2D ligand gene family.

Authors:  Masanori Kasahara; Shigeru Yoshida
Journal:  Immunogenetics       Date:  2012-07-29       Impact factor: 2.846

Review 6.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 7.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

Review 8.  Immune modulation in xenotransplantation.

Authors:  Magdalena Boksa; Joanna Zeyland; Ryszard Słomski; Daniel Lipiński
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-10-30       Impact factor: 4.291

Review 9.  Genetically Modified Pigs as Organ Donors for Xenotransplantation.

Authors:  Magdalena Hryhorowicz; Joanna Zeyland; Ryszard Słomski; Daniel Lipiński
Journal:  Mol Biotechnol       Date:  2017-10       Impact factor: 2.695

Review 10.  The Role of NK Cells in Pig-to-Human Xenotransplantation.

Authors:  Gisella Puga Yung; Mårten K J Schneider; Jörg D Seebach
Journal:  J Immunol Res       Date:  2017-12-19       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.